Overview
Vedolizumab is a gut-selective biologic that targets the α4β7 integrin on immune cells, preventing them from entering the intestinal lining. Because its action is confined to the gut, it has a favourable safety profile — particularly regarding infections — compared to systemic biologics. It is given as an intravenous infusion.
Key Uses
Moderate-to-severe ulcerative colitis
Moderate-to-severe Crohn's disease
Patients with prior TNF-blocker failure or intolerance
Preferred option when there are concerns about systemic immunosuppression (older patients, recurrent infections)
How It Works
Selectively blocks α4β7 integrin, preventing gut-homing immune cells from entering intestinal tissue
Gut-selective mechanism means minimal impact on systemic immunity
Induction: infusions at weeks 0, 2, and 6; maintenance: every 8 weeks
Onset of action may be slower than TNF blockers — patience is important
Subcutaneous maintenance formulation available as an alternative to infusions
Safety & Self-Care
Gut selectivity means lower risk of serious systemic infection compared to anti-TNF agents
TB and hepatitis B screening still required before starting
Avoid live vaccines; inactivated vaccines are safe
Nasopharyngitis (common cold-type infections) may be slightly more frequent
Attend all scheduled infusion appointments — consistency is key for maintaining remission
Contact Your IMCC Team
Contact your IMCC team if symptoms worsen, you develop signs of infection, you are planning pregnancy, or before any surgery or vaccination.
Share this with someone who needs it: